Synvista Therapeutics, Inc. (SYNI) Research

Synvista Therapeutics, Inc. functions as a biopharmaceutical company dedicated to creating both diagnostic tools and therapeutic drugs. Its core objective is to identify and provide treatment options for diabetic patients who are at an elevated risk of developing cardiovascular disease. The company's product portfolio includes ALT-2074, a glutathione peroxidase mimetic currently in Phase II clinical trials, which aims to treat diabetic patients with Hp2-2. Additionally, Synvista is advancing Alagebrium chloride (or alagebrium), an Advanced Glycation End-product Crosslink Breaker, also in Phase II trials, for its potential application in treating diastolic heart failure and diabetic nephropathy. Beyond its therapeutic pipeline, the firm is actively developing a diagnostic test specifically designed to detect and guide treatment for diabetic individuals prone to cardiovascular complications. Founded in 1986, the company was previously known as Alteon, Inc. and maintains its corporate headquarters in Montvale, New Jersey.

Open Synvista Therapeutics, Inc. (SYNI) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.